# PE-PE (NCT05578664)

> Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05578664
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: Consorzio Oncotech
- Conditions: Oligometastatic Renal Cell Carcinoma
- Interventions: Pembrolizumab injection plus metastasis directed treatment (surgery or RT); Tumor resection or RT
- Enrollment: 81
- Primary outcome: Relapsed Free Survival (RFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 6

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=pe-pe-nct05578664